There is also a difference in the organ specificity of adverse events, for example, colitis, hypophysitis and skin rashes occur more frequently with CTLA-4 inhibitors, while pneumonia, hyper- or hypo-thyroidism, joint pain and vitiligo are more common with PD-1 inhibitors [23]. Here, CTLA4 is linked to hypophysitis.